Renovorx Stock Net Income
| RNXT Stock | USD 0.97 0.03 3.00% |
RenovoRx fundamentals help investors to digest information that contributes to RenovoRx's financial success or failures. It also enables traders to predict the movement of RenovoRx Stock. The fundamental analysis module provides a way to measure RenovoRx's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to RenovoRx stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -8.2 M | -8.7 M | |
| Net Loss | -8.9 M | -9.3 M | |
| Net Loss | -9.2 M | -9.7 M | |
| Net Loss | (1.14) | (1.20) | |
| Net Income Per E B T | 1.14 | 1.17 |
RenovoRx | Net Income |
RenovoRx Company Net Income Analysis
RenovoRx's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current RenovoRx Net Income | (10.23 M) |
Most of RenovoRx's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, RenovoRx is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
RenovoRx Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for RenovoRx is extremely important. It helps to project a fair market value of RenovoRx Stock properly, considering its historical fundamentals such as Net Income. Since RenovoRx's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of RenovoRx's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of RenovoRx's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
RenovoRx Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, RenovoRx reported net income of (10.23 Million). This is 103.0% lower than that of the Biotechnology sector and 114.61% lower than that of the Health Care industry. The net income for all United States stocks is 101.79% higher than that of the company.
RenovoRx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RenovoRx's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of RenovoRx could also be used in its relative valuation, which is a method of valuing RenovoRx by comparing valuation metrics of similar companies.RenovoRx is currently under evaluation in net income category among its peers.
RenovoRx Current Valuation Drivers
We derive many important indicators used in calculating different scores of RenovoRx from analyzing RenovoRx's financial statements. These drivers represent accounts that assess RenovoRx's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of RenovoRx's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 63.9M | 28.0M | 14.8M | 22.4M | 25.8M | 44.5M |
RenovoRx Institutional Holders
Institutional Holdings refers to the ownership stake in RenovoRx that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of RenovoRx's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing RenovoRx's value.| Shares | Xtx Topco Ltd | 2024-12-31 | 12.6 K | Ubs Group Ag | 2024-12-31 | 12.3 K | Two Sigma Securities, Llc | 2024-12-31 | 11.7 K | Tower Research Capital Llc | 2024-12-31 | 817 | Citigroup Inc | 2024-12-31 | 384 | Bank Of America Corp | 2024-12-31 | 196 | Jpmorgan Chase & Co | 2024-12-31 | 40.0 | Family Firm Inc | 2024-09-30 | 0.0 | Blackrock Inc | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-12-31 | 235.7 K | Adar1 Capital Management Llc | 2024-12-31 | 197.2 K |
RenovoRx Fundamentals
| Return On Equity | -2.59 | ||||
| Return On Asset | -0.93 | ||||
| Current Valuation | 24.75 M | ||||
| Shares Outstanding | 35.57 M | ||||
| Shares Owned By Insiders | 1.28 % | ||||
| Shares Owned By Institutions | 2.85 % | ||||
| Number Of Shares Shorted | 205.91 K | ||||
| Price To Book | 4.85 X | ||||
| EBITDA | (11.39 M) | ||||
| Net Income | (10.23 M) | ||||
| Cash And Equivalents | 10.77 M | ||||
| Cash Per Share | 1.19 X | ||||
| Total Debt | 4.47 M | ||||
| Current Ratio | 10.01 X | ||||
| Book Value Per Share | 0.29 X | ||||
| Cash Flow From Operations | (10.26 M) | ||||
| Short Ratio | 1.12 X | ||||
| Earnings Per Share | (0.58) X | ||||
| Target Price | 5.5 | ||||
| Beta | 1.15 | ||||
| Market Capitalization | 35.39 M | ||||
| Total Asset | 1.47 M | ||||
| Retained Earnings | (41.41 M) | ||||
| Working Capital | 291 K | ||||
| Net Asset | 1.47 M |
About RenovoRx Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze RenovoRx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RenovoRx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RenovoRx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.